233 related articles for article (PubMed ID: 23682212)
1. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
Wattmo C; Paulsson E; Minthon L; Londos E
Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212
[TBL] [Abstract][Full Text] [Related]
2. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Wattmo C; Wallin AK; Minthon L
BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
[TBL] [Abstract][Full Text] [Related]
3. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
6. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
7. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
8. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
9. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
Wattmo C; Wallin ÅK; Londos E; Minthon L
Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
[TBL] [Abstract][Full Text] [Related]
11. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
Scacchi R; Gambina G; Broggio E; Corbo RM
Int J Geriatr Psychiatry; 2014 Jun; 29(6):610-5. PubMed ID: 24150894
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
14. Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.
Wattmo C; Londos E; Minthon L
Clin Interv Aging; 2014; 9():1951-62. PubMed ID: 25484578
[TBL] [Abstract][Full Text] [Related]
15. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
17. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
18. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Thompson S; Lanctôt KL; Herrmann N
Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
20. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
